Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

128
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
128
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

119
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
119
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

75
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
75
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

131
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
131
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

2.2K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.2K
Dosage Interval and Administration Route: Determination Methods01:19

Dosage Interval and Administration Route: Determination Methods

111
A medication’s effectiveness largely depends on its appropriate dosage and the route of administration. Dosage ensures that a sufficient drug concentration is maintained in the bloodstream to elicit the desired therapeutic effect without causing toxicity. The route of administration affects the drug's bioavailability, rate of absorption, and onset of action, which are crucial for achieving optimal therapeutic outcomes. Drug dosage calculations are critical to tailoring therapy to...
111

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low Back Pain: A Review.

JAMA·2026
Same author

Best Practices for Hospital-Based Initiation of Medications for Opioid Use Disorder: A Consensus Statement.

JAMA network open·2026
Same author

Leveraging the 72-Hour Rule Change to Support Transition From Hospital to Opioid Treatment Program.

JAMA network open·2025
Same author

Recommendations for Addressing In-Hospital Substance Use From a National Delphi Consensus Process.

JAMA network open·2025
Same author

North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition 2025 guidelines on the diagnosis of cyclic vomiting syndrome in children.

Journal of pediatric gastroenterology and nutrition·2025
Same author

Hospital-Based Methadone and Buprenorphine Initiation Practices by Addiction Consult Services.

JAMA network open·2025
Same journal

Substance-specific Mortality Risk Stratification Among Adults With Substance Use Disorders During Acute Respiratory Infection: A 3.4-Million-patient N3C Cohort Study.

Journal of addiction medicine·2026
Same journal

Exploring Diversion Concerns as a Modifiable Buprenorphine-prescribing Barrier Among Primary Care Professionals.

Journal of addiction medicine·2026
Same journal

Substance Use Among US Adults at Midlife: Risk Factors and Protective Factors Among National and Milwaukee Black American Samples.

Journal of addiction medicine·2026
Same journal

When "Kava" Isn't Kava: Opioid-like Withdrawal Responsive to Buprenorphine: A Case Study.

Journal of addiction medicine·2026
Same journal

The Association of Alcohol Withdrawal Severity Scales that Incorporate Vital Signs and Withdrawal Outcomes: A Multicenter Cohort Study.

Journal of addiction medicine·2026
Same journal

Changes in Exposures of US Children Ages 12 and Under to Cannabis from 2000 to 2024.

Journal of addiction medicine·2026
See all related articles

Related Experiment Video

Updated: Dec 8, 2025

Murine Neural Plate Targeting by In Utero Nano-Injection NEPTUNE at Embryonic Day 7.5
10:49

Murine Neural Plate Targeting by In Utero Nano-Injection NEPTUNE at Embryonic Day 7.5

Published on: February 14, 2022

4.2K

Hospital-based Buprenorphine Micro-dose Initiation.

Melissa B Weimer1, Michael Guerra, Gina Morrow

  • 1Department of Internal Medicine, Program in Addiction Medicine, Yale School of Medicine, New Haven, CT (MBW), Yale New Haven Hospital, New Haven, CT (MG, GM), University of Connecticut Mansfield, CT (KA).

Journal of Addiction Medicine
|September 22, 2020
PubMed
Summary
This summary is machine-generated.

Initiating buprenorphine treatment in hospitals can be difficult. This study introduces a new low-dose hospital strategy to help patients switch from full opioid agonists to buprenorphine, avoiding precipitated withdrawal.

More Related Videos

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

683
Engineered Vascularized Muscle Flap
08:18

Engineered Vascularized Muscle Flap

Published on: January 11, 2016

8.5K

Related Experiment Videos

Last Updated: Dec 8, 2025

Murine Neural Plate Targeting by In Utero Nano-Injection NEPTUNE at Embryonic Day 7.5
10:49

Murine Neural Plate Targeting by In Utero Nano-Injection NEPTUNE at Embryonic Day 7.5

Published on: February 14, 2022

4.2K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

683
Engineered Vascularized Muscle Flap
08:18

Engineered Vascularized Muscle Flap

Published on: January 11, 2016

8.5K

Area of Science:

  • Addiction Medicine
  • Pharmacology
  • Hospital Administration

Background:

  • Buprenorphine induction is challenging for patients with chronic pain or those unable to stop opioids, risking precipitated withdrawal.
  • Existing low-dose outpatient buprenorphine induction strategies are not suitable for hospital settings due to regulatory differences.
  • Hospital-based opioid use disorder treatment requires adaptable induction protocols.

Purpose of the Study:

  • To present a novel, low-dose buprenorphine initiation strategy specifically designed for the hospital setting.
  • To overcome barriers associated with transitioning patients from full opioid agonists to buprenorphine within a hospital environment.
  • To provide a generalizable model for hospital-based buprenorphine induction.

Main Methods:

  • Development of a novel low-dose buprenorphine induction protocol for inpatient use.
  • Implementation of the protocol to facilitate the transition from full opioid agonists.
  • Monitoring patient response and adherence to the new strategy.

Main Results:

  • The novel strategy successfully facilitated buprenorphine initiation in a hospital setting.
  • Patients were able to transition from full opioid agonists to buprenorphine without significant precipitated withdrawal.
  • The protocol demonstrated feasibility within hospital medication regulations.

Conclusions:

  • A low-dose, hospital-based buprenorphine initiation strategy can effectively manage patients transitioning from full opioid agonists.
  • This novel approach addresses challenges in hospital settings, improving treatment accessibility.
  • Further research should validate this strategy across diverse hospital populations and settings.